Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 73 publications

Rebalancing therapy for congenital hemophilia

Rebalancing therapy for congenital hemophilia

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: July 06, 2025

Curative Therapies for Hemophilias and Hemoglobinopathies in Adults: Immune, Gene, and Stem Cell Approaches in a Global Context.

Curative Therapies for Hemophilias and Hemoglobinopathies in Adults: Immune, Gene, and Stem Cell Approaches in a Global Context.

Journal: Biomedicines
Published: July 06, 2025

Fitusiran (Qfitlia) for hemophilia A and B.

Fitusiran (Qfitlia) for hemophilia A and B.

Journal: The Medical letter on drugs and therapeutics
Published: July 02, 2025

Pharmacokinetic evaluation of concizumab for the treatment of hemophilia.

Pharmacokinetic evaluation of concizumab for the treatment of hemophilia.

Journal: Expert opinion on drug metabolism & toxicology
Published: June 23, 2025

Anti-tissue factor pathway inhibitors for hemophilia: are these treatments the answer to overcoming current treatment limitations?

Anti-tissue factor pathway inhibitors for hemophilia: are these treatments the answer to overcoming current treatment limitations?

Journal: Expert review of hematology
Published: June 14, 2025

Rebalancing agents in hemophilia: knowns, unknowns, and uncertainties.

Rebalancing agents in hemophilia: knowns, unknowns, and uncertainties.

Journal: Haematologica
Published: May 16, 2025

Evaluating the Safety and Efficacy of Concizumab in Hemophilia A/B Patients: A Systematic Review.

Evaluating the Safety and Efficacy of Concizumab in Hemophilia A/B Patients: A Systematic Review.

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Published: May 14, 2025

Concizumab (Alhemo) for hemophilia A and B with inhibitors.

Concizumab (Alhemo) for hemophilia A and B with inhibitors.

Journal: The Medical letter on drugs and therapeutics
Published: May 05, 2025

Revolutionizing Treatment Strategies through Inhibition of Tissue Factor Pathway Inhibitor: A Promising Therapeutic Approach for Hemophilia Management.

Revolutionizing Treatment Strategies through Inhibition of Tissue Factor Pathway Inhibitor: A Promising Therapeutic Approach for Hemophilia Management.

Journal: The Journal of the Association of Physicians of India
Published: April 09, 2025

Erratum: The Concizumab Pen-Injector is Easy to Use and Preferred by Hemophilia Patients and Caregivers: A Usability Study Assessing Pen-Injector Handling and Preference [Corrigendum].

Erratum: The Concizumab Pen-Injector is Easy to Use and Preferred by Hemophilia Patients and Caregivers: A Usability Study Assessing Pen-Injector Handling and Preference [Corrigendum].

Journal: Patient preference and adherence
Published: March 19, 2025

Case Report: Severe hemophilia B patient with inhibitor and anaphylaxis reaction to FIX, successfully managed with concizumab prophylaxis therapy.

Case Report: Severe hemophilia B patient with inhibitor and anaphylaxis reaction to FIX, successfully managed with concizumab prophylaxis therapy.

Journal: Frontiers in pediatrics
Published: February 14, 2025

Concizumab, a Non-Replacement Therapy for Persons with Hemophilia with Inhibitors.

Concizumab, a Non-Replacement Therapy for Persons with Hemophilia with Inhibitors.

Journal: Journal of clinical medicine
Published: February 13, 2025
Showing 1-12 of 73

Last Updated: 10/31/2025